66 related articles for article (PubMed ID: 2362193)
1. In vivo fate of monoclonal antibody B72.3.
Halpern SE
J Nucl Med; 1990 Jul; 31(7):1143-6. PubMed ID: 2362193
[No Abstract] [Full Text] [Related]
2. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer.
Colcher D; Milenic DE; Ferroni P; Carrasquillo JA; Reynolds JC; Roselli M; Larson SM; Schlom J
J Nucl Med; 1990 Jul; 31(7):1133-42. PubMed ID: 2362192
[TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes.
Starling JJ; Maciak RS; Law KL; Hinson NA; Briggs SL; Laguzza BC; Johnson DA
Cancer Res; 1991 Jun; 51(11):2965-72. PubMed ID: 2032233
[TBL] [Abstract][Full Text] [Related]
4. Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients.
Roselli M; Hitchcock CL; Molinolo A; Milenic DE; Colcher D; Martin EW; Hinkle GH; Schlom J
Anticancer Res; 1995; 15(3):975-84. PubMed ID: 7645989
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of monoclonal antibody B72.3. Experimental and preclinical studies.
Colcher DM; Milenic DE; Schlom J
Targeted Diagn Ther; 1992; 6():23-44. PubMed ID: 1576348
[No Abstract] [Full Text] [Related]
6. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.
Colcher D; Milenic D; Roselli M; Raubitschek A; Yarranton G; King D; Adair J; Whittle N; Bodmer M; Schlom J
Cancer Res; 1989 Apr; 49(7):1738-45. PubMed ID: 2924317
[TBL] [Abstract][Full Text] [Related]
7. Tumor targeting with monoclonal antibody B72.3.
Schlom J; Colcher D; Roselli M; Carrasquillo JA; Reynolds JC; Larson SM; Sugarbaker P; Tuttle SE; Martin EW
Int J Rad Appl Instrum B; 1989; 16(2):137-42. PubMed ID: 2654088
[No Abstract] [Full Text] [Related]
8. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies.
Colcher D; Minelli MF; Roselli M; Muraro R; Simpson-Milenic D; Schlom J
Cancer Res; 1988 Aug; 48(16):4597-603. PubMed ID: 3396011
[TBL] [Abstract][Full Text] [Related]
10. Imaging of colorectal carcinoma with 131I B72.3 monoclonal antibody.
Carrasquillo JA
Targeted Diagn Ther; 1992; 6():45-55. PubMed ID: 1576349
[No Abstract] [Full Text] [Related]
11. The in vivo binding behaviour of an I-123 labelled anti-granulocytes antibody (Granuloszint).
Hasler PH; Novak-Hofer I; Bläuenstein P; Schubiger PA
Prog Clin Biol Res; 1990; 355():299-309. PubMed ID: 2281110
[No Abstract] [Full Text] [Related]
12. Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1.
Koda K; Glassy MC; McKnight ME; Yasutomi J; Saito N; Dan M; Nakajima N
Anticancer Res; 2001; 21(1B):621-7. PubMed ID: 11299816
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.
Muraro R; Kuroki M; Wunderlich D; Poole DJ; Colcher D; Thor A; Greiner JW; Simpson JF; Molinolo A; Noguchi P
Cancer Res; 1988 Aug; 48(16):4588-96. PubMed ID: 3396010
[TBL] [Abstract][Full Text] [Related]
14. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. The George N. Papanicolaou award lecture.
Johnston WW
Acta Cytol; 1987; 31(5):537-56. PubMed ID: 3314301
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the colorectal antigen IOR C2.II.
Vázquez AM; Tormo B; Velandia A; Gómez CA; Alfonso M; Giscombe R; Ansotegui I; Jeddi-Tehrani M; Pérez R; Mellstedt H
Year Immunol; 1993; 7():137-45. PubMed ID: 7690506
[No Abstract] [Full Text] [Related]
16. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen.
Divgi CR; Scott AM; McDermott K; Fallone PS; Hilton S; Siler K; Carmichael N; Daghighian F; Finn RD; Cohen AM
Nucl Med Biol; 1994 Jan; 21(1):9-15. PubMed ID: 9234259
[TBL] [Abstract][Full Text] [Related]
17. Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer.
Meredith RF; Khazaeli MB; Grizzle WE; Orr RA; Plott G; Urist MM; Liu T; Russell CD; Wheeler RH; Schlom J
Hum Antibodies Hybridomas; 1993 Oct; 4(4):190-7. PubMed ID: 8257773
[TBL] [Abstract][Full Text] [Related]
18. Oncologic theranostics: recognition of this concept in antigen-directed cancer therapy for colorectal cancer with anti-TAG-72 monoclonal antibodies.
Povoski SP; Hatzaras IS; Mojzisik CM; Martin EW
Expert Rev Mol Diagn; 2011 Sep; 11(7):667-70. PubMed ID: 21902525
[No Abstract] [Full Text] [Related]
19. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.
Fang L; Sun D
Drug Metab Dispos; 2008 Jun; 36(6):1153-65. PubMed ID: 18356268
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
